PRIMAEGISresearch
← Scenarios
LUPIN

Lupin Limited

Pharmaceuticals: Other/ NSE
Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target
LUPIN
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹2,415 today
BEAR
₹2,773
+15%
2.8% a year · 23.1x exit
BASE
₹4,468
+85%
4.9% a year · 36.5x exit
BULL
₹7,521
+211%
6.6% a year · 60.5x exit
FY27TODAY₹2,415 today₹7,521₹2,773₹4,468
Where the market has priced it
20x21x today132x
  • the last 3 years priced this company 26% below its ten-year median (27x vs 37x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
  • at 21x its FY26 earnings the stock trades below the bottom of its own ten-year range (23x)
  • the range is unusually wide — read it as the span of management's own claim, not as a forecast
  • this company's own median multiple sits 80% above its filed-industry peers; the scenario uses its own
How these numbers are produced
Earnings baseFY26 fiscal year EPS ₹116.65 (screener)
Guided growth4.9% a year, said on the call of 14-May-2026 · transcript
Read across asoperating: revenue growth, margin held flat — medium confidence
Delivery calibration0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple23.12x / 36.53x / 60.49x, this company’s own p20 / median / p80 across 8 filed years
Filed-industry peersmedian 20.34x across 3 peers — the cross-check, not the input
Arithmeticbase EPS × (1 + guided growth × delivery)1 × exit multiple
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

What management said

from NSE earnings-call filings · extracted, not interpreted
revenue growth 5%generic growth 5%margin 27%
As mentioned in our earlier interactions, we expect to grow our top line highsingle digits with margins at around 25% in FY27, despite increased headwinds from an uncertain geopolitical environment.
Call 14-May-2026 · bridge confidence medium · transcript PDF